Peter Heining

2.0k total citations · 1 hit paper
13 papers, 1.6k citations indexed

About

Peter Heining is a scholar working on Molecular Biology, Small Animals and Immunology. According to data from OpenAlex, Peter Heining has authored 13 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 3 papers in Small Animals and 3 papers in Immunology. Recurrent topics in Peter Heining's work include Sphingolipid Metabolism and Signaling (4 papers), Animal testing and alternatives (3 papers) and Monoclonal and Polyclonal Antibodies Research (2 papers). Peter Heining is often cited by papers focused on Sphingolipid Metabolism and Signaling (4 papers), Animal testing and alternatives (3 papers) and Monoclonal and Polyclonal Antibodies Research (2 papers). Peter Heining collaborates with scholars based in Switzerland, United States and United Kingdom. Peter Heining's co-authors include Gordon Francis, P Burtin, Shreeram Aradhye, Robert Schmouder, Volker Brinkmann, Thomas Baumruker, Andreas Billich, Guy Meno‐Tetang, Hongshan Li and William J. Jusko and has published in prestigious journals such as Neurology, Nature Reviews Drug Discovery and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Peter Heining

13 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

2010 1.0k citations Volker Brinkmann, Andreas Billich et al. Nature Reviews Drug Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Peter Heining Switzerland	10	1.1k	339	320	194	188	13	1.6k
Deborah Card United States	17	1.6k 1.4×	174 0.5×	687 2.1×	277 1.4×	142 0.8×	21	2.3k
Jing Su China	17	1.3k 1.2×	116 0.3×	395 1.2×	179 0.9×	127 0.7×	50	1.9k
Chang‐Wook Lee United States	14	1.9k 1.7×	200 0.6×	230 0.7×	436 2.2×	214 1.1×	21	2.3k
Tinggui Yin United States	19	858 0.8×	188 0.6×	363 1.1×	144 0.7×	147 0.8×	26	1.5k
Tina M. Thornton United States	16	1.1k 1.0×	146 0.4×	371 1.2×	153 0.8×	54 0.3×	21	1.7k
Christine Loh United States	17	997 0.9×	85 0.3×	297 0.9×	157 0.8×	59 0.3×	34	1.6k
Yuchan Wang China	24	1.1k 1.0×	113 0.3×	135 0.4×	126 0.6×	92 0.5×	87	1.7k
Shawn G. Payne United States	20	2.6k 2.4×	213 0.6×	371 1.2×	800 4.1×	154 0.8×	24	2.9k
Olaf Merkel Austria	21	921 0.8×	306 0.9×	235 0.7×	85 0.4×	68 0.4×	40	1.5k
Anna Jurewicz Poland	18	638 0.6×	252 0.7×	468 1.5×	77 0.4×	210 1.1×	32	1.5k

Countries citing papers authored by Peter Heining

Since Specialization

Citations

This map shows the geographic impact of Peter Heining's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Heining with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Heining more than expected).

Fields of papers citing papers by Peter Heining

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Heining. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Heining. The network helps show where Peter Heining may publish in the future.

Co-authorship network of co-authors of Peter Heining

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Heining. A scholar is included among the top collaborators of Peter Heining based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Heining. Peter Heining is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Colleton, Curtis, David Brewster, Anne Chester, et al.. (2016). The Use of Minipigs for Preclinical Safety Assessment by the Pharmaceutical Industry. Toxicologic Pathology. 44(3). 458–466. 28 indexed citations

Weaver, Margaret L., Joanna L. Parish, Ingrid Brück Bøgh, et al.. (2015). Vehicle Systems and Excipients Used in Minipig Drug Development Studies. Toxicologic Pathology. 44(3). 367–372. 9 indexed citations

Mahl, Andreas, et al.. (2015). The Potential of Minipigs in the Development of Anticancer Therapeutics. Toxicologic Pathology. 44(3). 391–397. 1 indexed citations

Heining, Peter & Tristan Ruysschaert. (2015). The Use of Minipig in Drug Discovery and Development. Toxicologic Pathology. 44(3). 467–473. 23 indexed citations

Karlsson, Goeril, Gordon Francis, Gideon Koren, et al.. (2014). Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology. 82(8). 674–680. 107 indexed citations

Pan, Shifeng, Nathanael S. Gray, Wenqi Gao, et al.. (2013). Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator. ACS Medicinal Chemistry Letters. 4(3). 333–337. 130 indexed citations

Brinkmann, Volker, Andreas Billich, Thomas Baumruker, et al.. (2010). Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nature Reviews Drug Discovery. 9(11). 883–897. 1015 indexed citations breakdown →

Brinkmann, Volker, Andreas Billich, Thomas Baumruker, et al.. (2010). Erratum: Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nature Reviews Drug Discovery. 9(12). 955–955. 5 indexed citations

Meno‐Tetang, Guy, Hongshan Li, Nancy A. Pyszczynski, et al.. (2006). Physiologically Based Pharmacokinetic Modeling of FTY720 (2-Amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in Rats After Oral and Intravenous Doses. Drug Metabolism and Disposition. 34(9). 1480–1487. 119 indexed citations

10.

Li, Hongshan, Guy Meno‐Tetang, Kenji Chiba, et al.. (2002). Pharmacokinetics and Cell Trafficking Dynamics of 2-Amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol Hydrochloride (FTY720) in Cynomolgus Monkeys after Single Oral and Intravenous Doses. Journal of Pharmacology and Experimental Therapeutics. 301(2). 519–526. 26 indexed citations

11.

Fredericks, Salim, et al.. (2001). Cardiac troponins and creatine kinase content of striated muscle in common laboratory animals. Clinica Chimica Acta. 304(1-2). 65–74. 60 indexed citations

12.

Bentley, P., et al.. (2000). The Industry View on Long‐Term Toxicology Testing in Drug Development of Human Pharmaceuticals. Pharmacology & Toxicology. 86(s1). 1–5. 9 indexed citations

13.

Mahl, Andreas, et al.. (2000). Comparison of clinical pathology parameters with two different blood sampling techniques in rats: retrobulbar plexus versus sublingual vein. Laboratory Animals. 34(4). 351–361. 35 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact